Kahealani Uehara

Kahealani Uehara

Auto-generated profile, based on publicly available information

Kahealani Uehara

Institute for Diabetes, Obesity, and Metabolism

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SZSteven Zhao
Steven Zhao
CJCholsoon Jang
Cholsoon Jang
JLJoyce Liu
Joyce Liu
KUKahealani Uehara
Kahealani Uehara
MGMichael Gilbert
Michael Gilbert
KWKathryn E. Wellen
Kathryn E. Wellen

24 May 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PDPieterjan Dierickx
Pieterjan Dierickx
MEMatthew J. Emmett
Matthew J. Emmett
CJChunjie Jiang
Chunjie Jiang
KUKahealani Uehara
Kahealani Uehara
MLManlu Liu
Manlu Liu
MLMitchell Avery Lazar
Mitchell Avery Lazar
The nuclear receptors REV-ERBα and -β link circadian rhythms and metabolism. Like other nuclear receptors, REV-ERB activity can be regulated by ligands, including naturally occurring heme. A putative ligand, SR9009, has been reported to elicit a range of beneficial effects in healthy as well as diseased animal models and cell systems. However, the direct involvement of REV-ERBs in these effects of SR9009 has not been thoroughly assessed, as experiments were not performed in the complete absence of both proteins. Here, we report the generation of a mouse model for conditional genetic deletion of REV-ERBα and -β. We show that SR9009 can decrease cell viability, rewire cellular metabolism, and alter gene transcription in hepatocytes and embryonic stem cells lacking both REV-ERBα and -β. Thus, the effects of SR9009 cannot be used solely as surrogate for REV-ERB activity.

15 April 2022 in Science
Verified
Journal Article
Closed access
BGBridget S. Gosis
Bridget S. Gosis
SWShogo Wada
Shogo Wada
CTChelsea Thorsheim
Chelsea Thorsheim
KLKristina Li
Kristina Li
SJSunhee Jung
Sunhee Jung
ZAZoltan Arany
Zoltan Arany
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis. We show that selective inhibition of mTORC1 signaling in mice, through deletion of the RagC/D guanosine triphosphatase–activating protein folliculin (FLCN), promotes activation of transcription factor E3 (TFE3) in the liver without affecting other mTORC1 targets and protects against NAFLD and NASH. Disease protection is mediated by TFE3, which both induces lipid consumption and suppresses anabolic lipogenesis. TFE3 inhibits lipogenesis by suppressing proteolytic processing and activation of sterol regulatory element–binding protein-1c (SREBP-1c) and by interacting with SREBP-1c on chromatin. Our data reconcile previously conflicting studies and identify selective inhibition of mTORC1 as a potential approach to treat NASH and NAFLD.

5 December 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DMDhanunjay Mukhi
Dhanunjay Mukhi
LLLingzhi Li
Lingzhi Li
HLHongbo Liu
Hongbo Liu
TDTomohito Doke
Tomohito Doke
LKLakshmi P. Kolligundla
Lakshmi P. Kolligundla
KSKatalin Susztak
Katalin Susztak
Worldwide, over 800 million people are affected by kidney disease, yet its pathogenesis remains elusive, hindering the development of novel therapeutics. In this study, we used kidney-specific expression of quantitative traits and single-nucleus open chromatin analysis to show that genetic variants linked to kidney dysfunction on chromosome 20 target the acyl-CoA synthetase short-chain family 2 (ACSS2). By generating ACSS2-KO mice, we demonstrated their protection from kidney fibrosis in multiple disease models. Our analysis of primary tubular cells revealed that ACSS2 regulated de novo lipogenesis (DNL), causing NADPH depletion and increasing ROS levels, ultimately leading to NLRP3-dependent pyroptosis. Additionally, we discovered that pharmacological inhibition or genetic ablation of fatty acid synthase safeguarded kidney cells against profibrotic gene expression and prevented kidney disease in mice. Lipid accumulation and the expression of genes related to DNL were elevated in the kidneys of patients with fibrosis. Our findings pinpoint ACSS2 as a critical kidney disease gene and reveal the role of DNL in kidney disease.

1 May 2021 in Cell Reports
Verified
Journal Article
Open access
JSJaimarie Sostre-Colón
Jaimarie Sostre-Colón
KUKahealani Uehara
Kahealani Uehara
AWAnna E. Garcia Whitlock
Anna E. Garcia Whitlock
MGMatthew J. Gavin
Matthew J. Gavin
JIJeff Ishibashi
Jeff Ishibashi
PTPaul M. Titchenell
Paul M. Titchenell
Organismal stressors such as cold exposure require a systemic response to maintain body temperature. Brown adipose tissue (BAT) is a key thermogenic tissue in mammals that protects against hypothermia in response to cold exposure. Defining the complex interplay of multiple organ systems in this response is fundamental to our understanding of adipose tissue thermogenesis. In this study, we identify a role for hepatic insulin signaling via AKT in the adaptive response to cold stress and show that liver AKT is an essential cell-nonautonomous regulator of adipocyte lipolysis and BAT function. Mechanistically, inhibition of forkhead box O1 (FOXO1) by AKT controls BAT thermogenesis by enhancing catecholamine-induced lipolysis in the white adipose tissue (WAT) and increasing circulating fibroblast growth factor 21 (FGF21). Our data identify a role for hepatic insulin signaling via the AKT-FOXO1 axis in regulating WAT lipolysis, promoting BAT thermogenic capacity, and ensuring a proper thermogenic response to acute cold exposure.

30 January 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KUKahealani Uehara
Kahealani Uehara
WLWon Dong Lee
Won Dong Lee
MSMegan Stefkovich
Megan Stefkovich
Dipsikha BiswasDipsikha Biswas
Dipsikha Biswas
DSDominic Santoleri
Dominic Santoleri
PTPaul M. Titchenell
Paul M. Titchenell
In response to a meal, insulin drives hepatic glycogen synthesis to help regulate systemic glucose homeostasis. The mechanistic target of rapamycin complex 1 (mTORC1) is a well-established insulin target and contributes to the postprandial control of liver lipid metabolism, autophagy, and protein synthesis. However, its role in hepatic glucose metabolism is less understood. Here, we used metabolomics, isotope tracing, and mouse genetics to define a role for liver mTORC1 signaling in the control of postprandial glycolytic intermediates and glycogen deposition. We show that mTORC1 is required for glycogen synthase activity and glycogenesis. Mechanistically, hepatic mTORC1 activity promotes the feeding-dependent induction of Ppp1r3b , a gene encoding a phosphatase important for glycogen synthase activity whose polymorphisms are linked to human diabetes. Reexpression of Ppp1r3b in livers lacking mTORC1 signaling enhances glycogen synthase activity and restores postprandial glycogen content. mTORC1-dependent transcriptional control of Ppp1r3b is facilitated by FOXO1, a well characterized transcriptional regulator involved in the hepatic response to nutrient intake. Collectively, we identify a role for mTORC1 signaling in the transcriptional regulation of Ppp1r3b and the subsequent induction of postprandial hepatic glycogen synthesis.